Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Keith Pratz"'
Autor:
Mark Litzow, Zhuoxin Sun, Ryan Mattison, Elisabeth Paietta, Charles Mullighan, Kathryn Roberts, Yanming Zhang, Janis Racevskis, Cheryl Willman, Matthew Wieduwilt, Michaela Liedtke, Julie Bergeron, Hillard Lazarus, Dan Arber, Brent Wood, Jacob Rowe, Keith Pratz, Shira Dinner, Noelle Frey, Steve Gore, Bhavana Bhatnagar, Ehab Atallah, Geoff Uy, Deepa Jeyakumar, Tara Lin, Shejal Patel, Michelle Elliott, Anjali Advani, Daniel Deangelo, Dimitrios Tzachanis, Pankit Vachhani, Rupali Bhave, Richard Little, Harry Erba, Richard Stone, Selina Luger, Martin Tallman
Publikováno v:
HemaSphere, Vol 7, p e1944062 (2023)
Externí odkaz:
https://doaj.org/article/4a4e6f30613c4e578971556fc0741d72
Autor:
Keith Pratz, Catherine Lai, Brian A. Jonas, Courtney Dinardo, Cat N. Bui, Rajesh Kamalakar, Jalaja Potluri, Wei-Han Chang, Rohini Sen, Thomas W Leblanc
Publikováno v:
HemaSphere, Vol 7, p e925140d (2023)
Externí odkaz:
https://doaj.org/article/c2d7a933cbe240418dc2b574c491f41c
Autor:
Keith Pratz, Courtney Dinardo, Martha L Arellano, Michael Thirman, Vinod Pullarkat, Pamela S. Becker, B. Douglas Smith, Meng Zhang, Michael E Werner, Jalaja Potluri, Daniel A. Pollyea
Publikováno v:
HemaSphere, Vol 7, p e68978fe (2023)
Externí odkaz:
https://doaj.org/article/9d932cfaecc64a378a4df2ef7714d55c
Autor:
Craig W. Freyer, Alison Carulli, Shannon Gier, Alex Ganetsky, Colleen Timlin, Mindy Schuster, Daria Babushok, Noelle V. Frey, Saar I. Gill, Elizabeth O. Hexner, Selina M. Luger, James K. Mangan, Mary Ellen Martin, Shannon R. McCurdy, Alexander E. Perl, David L. Porter, Keith Pratz, Jacqueline Smith, Edward A. Stadtmauer, Alison W. Loren
Publikováno v:
Leukemia & Lymphoma. 63:1925-1933
Patients undergoing haploidentical or mismatched unrelated donor (haplo/MMUD) allogeneic hematopoietic cell transplantation (alloHCT) receiving post-transplant cyclophosphamide (PTCy) are at high risk of cytomegalovirus (CMV) infection. Experience wi
Autor:
Brian A. Jonas, Andrew H. Wei, Christian Recher, Courtney D. DiNardo, Jun‐Ho Jang, Keith Pratz, Panayiotis Panayiotidis, Pau Montesinos, Su‐Peng Yeh, Vladimir Ivanov, Walter Fiedler, Takahiro Yamauchi, Yinghui Duan, Wellington Mendes, Jalaja Potluri, Björn Tews, Yishai Ofran
Publikováno v:
AMERICAN JOURNAL OF HEMATOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bbd07d351541ee6499a5dde4ef5ade3
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=15929
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=15929
Autor:
Courtney DiNardo, Keith Pratz, Panayiotis Panayiotidis, Xudong Wei, Vladimir Vorobyev, Árpàd Illés, Inho Kim, Vladimir Ivanov, Grace Ku, Catherine Miller, Meng Zhang, Fernando Tatsch, Jalaja Potluri, Xenia Schmidt, Christian Recher
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S124
Autor:
Courtney DiNardo, Keith Pratz, Panayiotis Panayiotidis, Xudong Wei, Vladimir Vorobyev, Àrpád Illés, Inho Kim, Vladimir Ivanov, Grace Ku, Catherine Miller, Meng Zhang, Fernando Tatsch, Jalaja Potluri, Xenia Schmidt, Christian Recher
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S214
Autor:
Shailly, Mehrotra, Mathangi, Gopalakrishnan, Jogarao, Gobburu, Jacqueline M, Greer, Richard, Piekarz, Judith E, Karp, Keith, Pratz, Michelle A, Rudek
Publikováno v:
British journal of clinical pharmacology. 83(8)
Veliparib is a potent inhibitor of poly(ADP-ribose) polymerase (PARP) enzyme. The objectives of the analysis were to evaluate the effect of baseline covariates and co-administration of topotecan plus carboplatin (T + C) on pharmacokinetics of velipar
Autor:
Keith Pratz, Mohamad Cherry, Jessica K. Altman, Brenda W. Cooper, Jose Carlos Cruz, Joseph G. Jurcic, Mark J. Levis, Tara L. Lin, Alexander E. Perl, Nikolai A. Podoltsev, Gary J. Schiller, Chaofeng Liu, Erkut Bahceci
Publikováno v:
Blood. 130:722-722
Background: Gilteritinib is a novel, potent, highly-selective oral fms -like tyrosine kinase 3 (FLT3)/AXL inhibitor with clinical activity in relapsed/refractory (R/R) AML with activating FLT3-ITD and -TKD mutations. In such patients, once-daily gilt